Zhongshan-based company Akeso, with its self-developed, globally first-in-class PD-1/CTLA-4 bispecific antibody cadonilimab injection (开坦尼®), has been featured on the 2025 list of "Manufacturing Single Champion Enterprises of Guangdong," recently published by the Department of Industry and Information Technology of Guangdong Province.

A "manufacturing single champion" refers to an enterprise that has long specialized in specific manufacturing niches, possesses robust innovation capabilities and leading-edge production technologies/processes at both domestic and international levels, and ranks among the top globally or nationally in market share for a single product.